and IL-23. Our findings suggest that ERK MAP kinase plays a critical and hitherto undescribed role in activating innate production of IL-23 and IL-1β, which promote pathogenic T cell responses, and therefore represents an important target for therapeutic intervention against autoimmune diseases.
Introduction

IL-17-producing T cells (Th17 cells) and IFN-γ-secreting Th1 cells are discrete populations of inflammatory T cells that have distinct and possibly complementary roles in the pathogenesis
of autoimmune diseases and in protection against infection (1) (2) (3) (4) . The differentiation of Th1 cells is mediated by IL-12, while the IL-12 family member, IL-23, especially in synergy with IL-1, plays an essential role in the induction or expansion of murine and human Th17 cells (1, (5) (6) (7) . IL-6 or IL-21 with TGF-β can also promote the differentiation of Th17 cells from naïve
CD4
+ T cells (8, 9) . IL-1RI and IL-23 defective mice are resistant to the development of experimental autoimmune encephalomyelitis (EAE) (5, 10) . Furthermore, anti-IL-23 therapy reduced IL-17 concentrations in serum and in the CNS, and prevented disease relapse in relapsing-remitting EAE (11) . Consequently, IL-23 and IL-17 are now considered to be important new targets for treating autoimmune diseases in humans (12) . In contrast, the roles of IL-12 and IFN-γ are less clear, with evidence for suppression of Th17 development by IFN-γ (2, 3) and exacerbated autoimmunity in IL-12 or IFN-γ defective mice (10, 13) , but also reports that Th1 cells do have pathogenic roles in certain autoimmune diseases (14) (15) (16) .
IL-12 and IL-23 are produced by cells of the innate immune system, such as dendritic cells (DC), following binding of pathogen associated molecular patterns (PAMPs) or endogenous danger signals to TLR, NOD-like receptor (NLR) or other pathogen-recognition receptors (PRRs), such as dectin-1 (6, 7) . However, the induction of IL-12 and IL-23 are differentially regulated by TLR and NLR-activated DC (7) . NFκB, interferon regulatory factor (IRF)1 and IRF8 signalling pathways play important roles in the expression of IL-12p35 and IL-12p40 and in driving Th1 responses (17) (18) (19) (20) . In contrast, it has been demonstrated that IL-6
and IL-23 production in DC by agonists of dectin-1, and consequent development of Th17 cells, is mediated by signalling via Syk and CARD9 (21) . However, the signalling molecules involved in promoting the IL-23 production are still unclear. A study on the role of IRF-1 demonstrated that this transcriptional factor was essential for IL-12-driven Th1 responses, but was not required for IL-23-dependent IL-17 production (20) .
In this study we examined the role of ERK MAP kinase in TLR-induced IL-23 and IL-1β production by DC and the subsequent expansion of Th17 cells. We found that inhibition of MEK1/2, the kinase upstream of ERK, suppressed IL-23 and IL-1β production by DC stimulated with the TLR4 agonist, LPS, but also with the dectin-1 agonist, curdlan and with heat killed Mycobacteria tuberculosis. In contrast, IL-12p70 production was not affected by inhibition of ERK activation. Adoptive transfer experiments with antigen-pulsed and TLR 
Statistical analysis
Data were compared by unpaired t-test or by one-or two-way ANOVA. Where significant differences were found, the Tukey-Kramer multiple comparisons test was used to identify differences between individual groups.
Results
ERK MAP kinase is required for IL-23, but not IL-12, production by DC
Previous studies had suggested that distinct signalling pathways were required for production of IL-12 and IL-23 and the development of Th1 and Th17 cells (18 and IL-1β, but not IL-12p70 production by LPS-activated DC (Fig. 1B) . Furthermore, LPSinduced IL-23p19 and IL-1β, but not IL-12p35, mRNA expression in DC was suppressed by the ERK inhibitor (Fig. 1C) .
The suppressive effect of the MEK1/2 inhibitor on IL-23 and IL-1β production was not confined to TLR4 activation, as U0126 also suppressed IL-23 and IL-1β production by DC in response to the dectin-1 agonist, curdlan (Fig. 2) . Furthermore, suppression of LPS-or curdlan-induced IL-23 and IL-1β was observed with 3 distinct inhibitors of MEK1/2, UO126, PD98059 and a commercially available (Calbiochem) MEK1/2 inhibitor over a range of inhibitor concentrations (Fig 2) .
Since M. tuberculosis includes a range of PAMPs and is used as the adjuvant to induce many experimental autoimmune diseases in mice, including EAE, we examined the effect of inhibiting ERK signalling on cytokine production by DC stimulated with heat killed M.
tuberculosis. Incubation of DC with U0126 suppressed IL-1β and IL-23 production but had little effect on IL-12p40 production in response to heat-killed M. tuberculosis (Fig. 3 ). (Fig. 6A ). This was associated with significant suppression of PLP-specific IL-17 production (Fig. 6B ). These findings demonstrate that inhibition of ERK attenuates the development of acute EAE when administered during the induction phase and also prevents relapse in the relapsing-remitting model of EAE. Furthermore, the attenuation is associated with significant suppression of autoantigen-specific IL-17 production.
MOG-specific T cells expanded with antigen in the presence of IL-1 and IL-23 induce EAE following adoptive transfer in vivo
We The results showed that IL-23 significantly enhanced MOG-induced IL-17 production and that this was further augmented by addition of IL-1β (Fig 7A) . In contrast, IFN-γ production was enhanced by culture with MOG in the presence of IL-1β, but was this was not further augmented by addition of IL-23 (Fig. 7A) .
We next examined the ability of MOG-specific T cells activated in vitro with MOG, IL-1β and IL-23 to transfer EAE to naive mice. Lymph node and spleen cells from mice with EAE cultured in vitro with MOG alone, which produced IFN-γ but low levels of IL-17 ( Fig   7B) , did not induce EAE following adoptive transfer to naïve mice ( Fig 7C) . In contrast,
transfer of MOG-specific T cells cultured in vitro in the presence of IL-1 and IL-23, which expanded a mixed population of Th1 and Th17 cells ( Fig 7D) . Treatment with the ERK inhibitor at the time of T cell transfer resulted in a modest, but statistically non-significant, attenuation of EAE (Fig 7D) . In contrast, transfer of DC pulsed in vitro with MOG and MTB induced mild EAE, which was completely suppressed when the cells were cultured with MOG and MTB in the presence of the ERK inhibitor (Fig.   7E ). These findings suggest that in our system, a major effect of the ERK inhibitor is to suppress MTB-induced IL-1 and IL-23 production by DC, which promote induction of IL-17-producing T cells, but that the ERK inhibitor may also suppress endogenous IL-1 and IL-23 production in vivo, required for expansion or survival of Th17 cells.
The attenuating effect of the ERK inhibitor on Th17 and Th1 responses and EAE is mediated via suppression of IL-1 and IL-23 production
In order to confirm that the suppressive effect of the ERK inhibitor on Th17 responses and on MOG-specific IL-17 production was also enhanced, but not significantly when mice were immunized with MOG and CFA in the presence of IL-1β and IL-23, without the ERK inhibitor (Fig. 8A) . Intracellular cytokine staining on lymph node cells from mice immunized with MOG and CFA revealed that the frequency of IL-17 producing by CD3 + T cells was reduced by administration of the ERK inhibitor, and this was reversed by co-administration of IL-23 (Fig. 8B) . Assessment of IL-17 production by CD4 + T cells confirmed that treatment with UO126 suppressed the development of Th17 cells, which was reversed by administration of IL-23 in vivo (Fig. 8B ).
We also examined the effect of IL-1β and IL-23 on the suppressive effect of the ERK inhibitor on the course of disease in the EAE model. Consistent with our earlier data, treatment with the ERK inhibitor significantly reduced the symptoms of EAE (Fig. 8C) . The attenuating effect of the ERK inhibitor on the development of EAE was reversed by coadministration of IL-1β and IL-23 (Fig. 8C) . Treatment with IL-1β and IL-23 in the absence of the ERK inhibitor did not alter the course of disease. These findings suggest that the ERK inhibitor attenuates the clinical signs of EAE by suppressing IL-1β and IL-23 production.
Discussion
It has previously been reported that MyD88-mediated activation of NFκB, IRF-1 and IRF-8
are required for IL-12p35 and IL-12p40 gene expression and driving Th1 responses (17) (18) (19) (20) .
However, these studies failed to find a role for these transcriptional factors in IL-23-driven
Th17 responses and suggested that alternative signalling molecules may be involved (18, 20) .
Our study demonstrates that ERK MAPK is an essential component of an alternative pathway (10, 14) . Furthermore, treatment with anti-IL-23 can suppress IL-17 production and attenuate clinical signs of autoimmunity in EAE and EAU models (11, 14) .
In the EAE model, adoptive transfer of T cells from WT into IL-23p19 -/-mice or IL-1RI
-/-mice, demonstrated that IL-23 and IL-1 play a critical role in the development of Th17 cells (5, 28) .
This study has shown that inhibition of MEK1/2 suppresses the clinical signs of disease in two EAE models by suppressing autoantigen-specific T cell responses. It has previously been reported that ERK1 -/-mice have increased susceptibility to EAE (29). While these findings appear to be at variance with our study, they are not directly comparable, as the MEK1/2 inhibitors used in our study block ERK1 and ERK2, whereas the knock out mice are only defective in ERK1. Furthermore, the ERK inhibitor was only administered during or after the induction of EAE, whereas the knockout mice lack ERK1 through the course of their development. Interestingly, we previously reported that inhibition of ERK enhanced IL-17 production by T cells in vitro (5) , whereas the present study shows that inhibition of ERK 
